-
公开(公告)号：US20220246265A1
公开(公告)日：2022-08-04
申请号：US17592223
申请日：2022-02-03
Applicant: Dexcom, Inc.
Inventor： Stephen D. Patek
Abstract: Systems and methods are provided for managing hyperglycemia and hypoglycemia by reconciling incoming data to provide safe and reliable control to range using automatic bolus determination wherein the rate of insulin delivery is dependent on the level of hyperglycemic risk or hypoglycemic risk. Additionally, some implementations are directed to converting insulin delivery into a rate based on glycemic risk.
-
公开(公告)号：US20220246264A1
公开(公告)日：2022-08-04
申请号：US17592071
申请日：2022-02-03
Applicant: Dexcom, Inc.
Inventor： Stephen D. Patek
Abstract: Systems and methods are provided for managing hyperglycemia and hypoglycemia by reconciling incoming data to provide safe and reliable control to range using automatic bolus determination wherein the rate of insulin delivery is dependent on the level of hyperglycemic risk or hypoglycemic risk. Additionally, some implementations are directed to converting insulin delivery into a rate based on glycemic risk.
-
公开(公告)号：US20210151190A1
公开(公告)日：2021-05-20
申请号：US17096785
申请日：2020-11-12
Applicant: Dexcom, Inc.
Inventor： Stephen D. Patek
IPC: G16H50/20 , G16H20/17 , G16H10/60 , G06F16/23 , G16H50/70 , G16H10/20 , G16H50/50 , G16H20/60 , G16H20/30 , A61B5/00 , A61B5/145 , A61M5/172
Abstract: Systems and methods are provided for reconciling untrusted data of a subject using trusted data pertaining to the subject. Systems and methods are directed to evaluating differences in predicted data with respect to corresponding received data. Systems and methods estimate metabolic states from a combination of trusted and untrusted metabolic inputs, along with optionally using a personalized mathematical model with parameter optimization. Systems and methods provide for reconciled untrusted inputs with their measured impact of the glycemic signals that is consistent with a metabolic model. Estimation of future metabolic states for decision support and automated insulin dosing is enabled. Replay of scenarios with estimated or reconciled data is also provided.
-
公开(公告)号：US12144658B2
公开(公告)日：2024-11-19
申请号：US18219845
申请日：2023-07-10
Applicant: Dexcom, Inc.
Inventor： Stephen D. Patek , Stephen J. Vanslyke
Abstract: An amount of glycemic dysfunction associated with mis-timing (e.g., delay) of meal boluses based on replay analysis is determined. The amount of dysfunction of historical or estimated bolusing as compared to an optimally timed bolus based on the replay analysis is quantified and visualized. Inferences may be made about diabetes meal management regarding inputs from a patient.
-
公开(公告)号：US20240058532A1
公开(公告)日：2024-02-22
申请号：US18383133
申请日：2023-10-24
Applicant: Dexcom, Inc.
Inventor： Stephen D. Patek , Matthew S. Gerber , Enrique Campos-Nanez , Thibault Gautier , Leah Ziegler
CPC classification number: A61M5/1723 , A61M5/16877
Abstract: A continuous glucose monitor (CGM)-driven basal insulin titration system and method for patients with Type 2 Diabetes can be adapted to the needs and concerns of subjects just starting on basal insulin therapy. The method uses as inputs historical CGM data, basal insulin dose information, reports of hypoglycemia, and past recommendations and generates an adjusted insulin dose along with a report advising whether to continue the titration process, or to stop. The method can generate a new recommendation on a regular basis (e.g., each day) until it determines an adequate, consistent dose size.
-
Patent Agency Ranking
公开(公告)号：US11696728B2
公开(公告)日：2023-07-11
申请号：US16721810
申请日：2019-12-19
Applicant: DexCom, Inc.
Inventor： Stephen D. Patek , Stephen J. Vanslyke
CPC classification number: A61B5/7275 , A61B5/4833 , G16H10/60 , G16H20/60 , G16H50/30 , G16H70/20 , A61B5/14532 , A61M2230/201 , C07K14/62
Abstract: An amount of glycemic dysfunction associated with mis-timing (e.g., delay) of meal boluses based on replay analysis is determined. The amount of dysfunction of historical or estimated bolusing as compared to an optimally timed bolus based on the replay analysis is quantified and visualized. Inferences may be made about diabetes meal management regarding inputs from a patient.
-
公开(公告)号：US20210193287A1
公开(公告)日：2021-06-24
申请号：US17123598
申请日：2020-12-16
Applicant: DexCom, Inc.
Inventor： Stephen D. Patek
Abstract: Systems and methods are provided for identifying therapeutic zones where there is glycemic dysfunction of a specific type that can be addressed by making strategic changes to behavior and/or therapy parameters. Systems and methods described herein evaluate large historical data sets to: identify a therapeutic zone or zones with glycemic dysfunction that are most readily addressable; quantify the glycemic impact of a plurality of different therapeutic adjustments in terms of either adjustments to historical doses or the parameters of a prospective dosing strategy to determine the highest possible improvement; and/or identify patient dosing strategies to provide therapy recommendations adapted for the patient's preferred behavioral dosing strategy.
-
公开(公告)号：US20200205743A1
公开(公告)日：2020-07-02
申请号：US16721806
申请日：2019-12-19
Applicant: DexCom, Inc.
Inventor： Stephen D. Patek , Stephen J. Vanslyke
Abstract: An amount of glycemic dysfunction associated with mis-timing (e.g., delay) of meal boluses based on replay analysis is determined. The amount of dysfunction of historical or estimated bolusing as compared to an optimally timed bolus based on the replay analysis is quantified and visualized. Inferences may be made about diabetes meal management regarding inputs from a patient.
-
公开(公告)号：US11887715B2
公开(公告)日：2024-01-30
申请号：US16906812
申请日：2020-06-19
Applicant: DexCom, Inc.
Inventor： Stephen D. Patek , Enrique Campos-Náñez
IPC: G16H20/17 , G06N5/04 , G16H20/30 , G16H40/67 , G16H50/50 , G16H10/60 , G16H50/30 , G16H50/70 , G16H50/20 , G16H20/60
CPC classification number: G16H20/17 , G06N5/04 , G16H10/60 , G16H20/30 , G16H20/60 , G16H40/67 , G16H50/20 , G16H50/30 , G16H50/50 , G16H50/70
Abstract: Adaptive on board estimation of exogenous pharmacon responsive to transient (i.e., impermanent) physiological effects is provided. Dynamically estimating an equivalent amount of an exogenous pharmacon on board (XOB), such as insulin and/or carbohydrates, left in the subject, is based on predictions of glucose time-series data. These estimated values, such as insulin on board (IOB), are useful for diabetes management software, including decision support and/or artificial pancreas (AP) algorithms, for example.
-
公开(公告)号：US11804289B2
公开(公告)日：2023-10-31
申请号：US17123598
申请日：2020-12-16
Applicant: DexCom, Inc.
Inventor： Stephen D. Patek
IPC: G16H20/17 , G16H40/67 , A61B5/00 , G16H10/60 , A61B5/145 , G16H50/30 , G16H70/40 , G16H20/10 , G16H20/60 , G06F40/40 , G16H15/00 , G16H50/70 , G16H50/20 , G06F16/26 , A61M5/172
CPC classification number: G16H20/17 , A61B5/14532 , A61B5/7275 , G06F16/26 , G06F40/40 , G16H10/60 , G16H15/00 , G16H20/10 , G16H20/60 , G16H40/67 , G16H50/20 , G16H50/30 , G16H50/70 , G16H70/40 , A61M5/1723 , A61M2230/201
Abstract: Systems and methods are provided for identifying therapeutic zones where there is glycemic dysfunction of a specific type that can be addressed by making strategic changes to behavior and/or therapy parameters. Systems and methods described herein evaluate large historical data sets to: identify a therapeutic zone or zones with glycemic dysfunction that are most readily addressable; quantify the glycemic impact of a plurality of different therapeutic adjustments in terms of either adjustments to historical doses or the parameters of a prospective dosing strategy to determine the highest possible improvement; and/or identify patient dosing strategies to provide therapy recommendations adapted for the patient's preferred behavioral dosing strategy.
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.014 seconds)
